Leukapheresis Market Research Report 2023 - Global Opportunity/Analysis to 2028
25 sept. 2023 10h33 HE
|
Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma),...
Global Minimal Residual Disease (MRD) Market Size to Reach USD 4,138.5 Million in 2030 | Emergen Research
14 sept. 2023 09h51 HE
|
Emergen Research
Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...
ADC Therapeutics to Participate in September Investor Conferences
05 sept. 2023 07h00 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in...
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
30 août 2023 19h33 HE
|
ADC Therapeutics SA
LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in...
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 août 2023 16h30 HE
|
Marker Therapeutics
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
08 août 2023 07h00 HE
|
ADC Therapeutics SA
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio...
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
24 juil. 2023 07h21 HE
|
ADC Therapeutics SA
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE:...
Global Multiple Myeloma Market Research Report 2023-2030: Top 10 Markets, Epidemiology, Marketed Products, Pipeline Drugs, Patient Journey, Competitive Landscape
12 juin 2023 07h08 HE
|
Research and Markets
Dublin, June 12, 2023 (GLOBE NEWSWIRE) -- The "Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis"...
Global Gastric Cancer Market Expected to Accumulate a Revenue of $10,737.00 Million by 2031, Growing at a Healthy CAGR of 17.9% [350-Pages] | Initiative by Research Dive
01 juin 2023 09h02 HE
|
Research Dive
New York, USA, June 01, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global gastric cancer market is anticipated to rise at a stable CAGR of 17.9%, thereby...
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
01 juin 2023 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...